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SUMMARY 
At a population level, little is known regarding the risk of liver- and non-liver-related mortality 
and hospitalization and the development of hepatocellular carcinoma (HCC) in hepatitis C virus 
(HCV) infected patients with decompensated cirrhosis (DC). This large-scale national record-
linkage study estimates these outcomes following first hospital admission for DC. Record-linkages 
between national HCV diagnosis and clinical databases and the national inpatient hospital episode 
database and mortality register were conducted to follow up the disease course of all identified 
HCV-diagnosed and chronically-infected persons. The study population consisted of 1,169 HCV 
chronically-infected persons who had a first hospital admission for DC within the period 1994–
2013. We observed an overall average annual percentage change of 12.6% in new DC patients 
(from 63 in 1994-1999 to 541 in 2009-2013), with no evidence for any improvement in the relative 
risks of liver-related or all-cause death over time. Between 1 January 1994 and 31 May 2014, 722 
and 95 DC patients had died of a liver- and a non-liver related cause, respectively, and 106 patients 
had a subsequent first admission for HCC. The five-year cumulative incidence of liver-related 
mortality, non-liver related mortality, and first subsequent HCC admission was 61.3%, 8.2%, and 
8.8%, respectively. The health burden in HCV-infected patients associated with development of 
decompensated cirrhosis has increased dramatically over the last 20 years. Our findings establish 
the baseline mortality and HCC progression rates in DC patients against which the impact of new 
antiviral therapies can be measured. 
Keywords  Decompensated cirrhosis; hepatocellular carcinoma; mortality; Scotland; record-
linkage 
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INTRODUCTION 
One of the most severe sequelae of chronic infection with the hepatitis C virus (HCV) is 
decompensated cirrhosis (DC), which refers to clinical progression following the generally 
asymptomatic compensated phase of cirrhosis. Complications comprising DC include jaundice, 
variceal haemorrhage, ascites, and encephalopathy. An estimated 30% of patients with cirrhosis 
progress to DC within 10 years (1), with an estimated annual risk of 3–6% (1, 2). Mortality 
following DC without liver transplantation is very high – the annual mortality risk has been 
estimated in the range of 12–14% from small studies of HCV-infected patients (1, 2, 3). 
 
Historically, HCV-infected patients with decompensated liver disease have not been 
recommended for interferon-based treatment, due to a greater impact of adverse effects and a 
lower chance of successful viral clearance compared with treatment at the compensated stage of 
cirrhosis (4, 5). New interferon-free therapies with better tolerability, greater safety and simplified 
monitoring protocols promise improved treatment options for those with severe liver disease (6-8). 
Importantly, to assess the clinical value of these new therapies we need to have a thorough 
understanding of the extent of mortality and morbidity among DC patients. 
 
A national record-linkage study conducted previously in Scotland for the period 1991-2005 
reported an average annual increase of 10.7% in the number of new presentations with HCV-
related DC (9). The risk of developing DC in this population was found to be associated with 
epidemiological characteristics including older age, a history of problem alcohol use, and HIV co-
infection. Outcomes following DC were not investigated; in the current study, we expand upon 
this earlier research by setting this rising trend in the annual number of DC cases in context of the 
disease burden experienced by these patients. 
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Therefore, the principal purpose of this study is to further our understanding of the natural history 
of HCV-related DC during the pre-DAA (direct-acting antivirals) era, so that we can assess the 
impact of highly effective DAA regimens – now being introduced – on the risk of death from liver 
failure and the development of such complications as hepatocellular carcinoma (HCC). These 
findings will constitute a historical baseline against which future outcomes can be gauged. In the 
current study, we describe the frequency of liver-related and all-cause mortality and first-time 
hospital admissions for HCC among Scotland’s HCV-infected DC patient population, and report 
the risk of mortality and associated patient factors. 
 
MATERIALS AND METHODS 
Design  
The design was a retrospective cohort study, using record-linkage between national databases to 
determine the health burden among HCV chronically-infected persons who have reached the DC 
stage of liver disease. 
 
Data sources 
Health Protection Scotland maintains the HCV Diagnosis database, which is a database of all 
persons who have been diagnosed HCV positive in Scotland since testing began in 1991 (including 
stored serum back to 1985)(10). Laboratory detection of hepatitis C antibody positivity is a 
requirement for inclusion. This database contains the following limited non-named information: 
surname Soundex (a consonant-only phonetic encoding), forename initial, date of birth, sex, and 
postcode district of residence, as well as data concerning risk activities for acquiring infection. As 
of 31 December 2013, this database contained records for 35,474 individuals (11), while an 
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estimated 55% of the current HCV infected Scottish population have been diagnosed (12). 
 
The Scottish Hepatitis C Clinical database, also held at Health Protection Scotland, consists of data 
on all aspects of HCV care and patient management, installed across specialist HCV treatment 
centres in Scotland (see Ref. (13), for further details). 
 
Hospital admission data form the Scottish Morbidity Records, an episode-based patient record 
held by Information Services Division (a division of NHS National Services Scotland) of all general 
acute inpatient and day-case hospital discharges. Discharge diagnoses use International 
Classification of Diseases (ICD) Ninth Revision for discharges in the period 1989-1995, and the 
Tenth Revision for discharges between 1996 and 2014.  
 
Mortality data was provided by death registrations held by the National Records of Scotland 
(NRS), formerly the General Register Office for Scotland (GROS). Underlying and contributing 
causes of death are coded, as for the Scottish Morbidity Records, using the ICD Ninth Revision for 
deaths occurring in the period 1989-1995, and the Tenth Revision for deaths in 1996-2014. 
 
Record linkage 
Linkage of records between the HCV Diagnosis database and the Scottish Morbidity Records and 
death registrations was carried out by Information Services Division using probabilistic record-
linkage techniques (14); this methodology allows for matches using incomplete identifiers. The 
linked dataset was anonymized before transfer to HPS for analysis. Linkage between the HCV 
Diagnosis database and the Scottish Hepatitis C Clinical database was also conducted, to 
determine the HCV RNA status at baseline for those DC patients treated with antiviral therapy 
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(see Ref. (15) for further details). Linkages were approved by the Privacy Advisory Committee, 
which oversees confidentiality issues involving data held on NHS Scotland patients. 
 
Data analysis  
Study population  
The study population consisted of all HCV chronically-infected patients with diagnosed DC 
(defined as first inpatient/day-case hospital episode with a relevant ICD-9 or ICD-10 code in either 
the main or five supplementary diagnosis fields of the episode record) in Scotland over the period 
1994-2013, thus providing a 20-year study period. Individuals for whom their first DC hospital 
admission occurred >1 year before their HCV diagnosis were excluded, to reduce potential bias 
due to DC resulting from another aetiology. For the restriction to chronic infection, HCV RNA 
status for each DC patient was determined according to PCR test results (undertaken at the time of 
the initial HCV diagnosis, or otherwise post-completion of antiviral therapy) held on the HCV 
Diagnosis and Scottish Hepatitis C Clinical databases; all patients who had changed status from 
RNA-positive to RNA-negative as a result of successful antiviral therapy either before first DC 
admission (n=17) or at any time during follow-up (n=36) were also excluded.  
 
The DC codeset consisted of ascites (ICD-10 R18; ICD-9 789.5), bleeding oesophageal varices (ICD-
10 I85.0, I98.2, I98.3; ICD-9 456.0), chronic hepatic failure, including hepatic encephalopathy (ICD-
10 K72.1, K72.9; ICD-9 572.2, 572.8), alcoholic hepatic failure (K70.4), and hepatorenal syndrome 
(ICD-10 K76.7; ICD-9 572.4). These codes were common among those used in previous DC 
research (9, 16), and were selected in consultation with clinicians and epidemiologists working in 
the field of HCV infection. 
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Outcome measures and covariates  
We report three principal endpoints: liver-related mortality, all-cause mortality, and first HCC 
admission subsequent to first DC admission, based on the occurrence of a pre-defined set of ICD 
codes in either the underlying or contributing cause of death fields (mortality) or either the main 
or supplementary discharge diagnosis fields (hospital admissions). For the liver-related mortality 
endpoint, the set of ICD codes comprised alcoholic liver disease (ICD-10 K70; ICD-9 571.0–571.3), 
liver cancer (ICD-10 C22; ICD-9 155), non-alcoholic liver disease (ICD-10 K71–77; ICD-9 570, 571.4–
571.9, 572–573), viral hepatitis (ICD-10 B15–19; ICD-9 070), and sequelae of viral hepatitis (ICD-10 
B94.2, R17, R18, I85.0, I98.2, I98.3; ICD-9 789.5, 456.0) (17). For the endpoint first HCC admission, 
the codeset consisted of C22.0 and 155.0. Non-liver related mortality as an additional endpoint was 
also investigated. 
 
The covariates investigated consisted of: sex, five-year period of first DC admission (1994-1998, 
1999-2003, 2004-2008, 2009-2013), first alcohol-related hospital admission, risk group for HCV 
acquisition (people who inject drugs (PWID), non-PWID, not known), HIV co-infection, and 
primary DC discharge diagnosis code category. The binary indicator variable HIV co-infected 
status was determined by searching all linked hospitalization records for each patient; if an HIV 
code (defined as ICD-10 B20-24; ICD-9 042, V08) occurred in any episode, then the indicator 
variable was set to one. The three DC discharge diagnosis categories are hepatic failure (aggregating 
the diagnosis codes comprising chronic hepatic failure, alcoholic hepatic failure, and hepatorenal 
syndrome), ascites, and bleeding varices (see above). We use the terms admission and discharge 
equivalently, assuming that discharge diagnoses encode the reason(s) for admission. 
 
Four time-dependent covariates were also included: (i) current age (< 40, 40–49, 50–59, and 60+ 
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years) captures changing membership of 10-year age groups throughout the study period; (ii) date 
of first HCC hospital admission, if this occurred; (iii) date of first hospital admission with a post-
liver transplant diagnosis code, if this occurred (‘liver transplant status’: ICD-10 Z94.4; ICD-9 
V42.7); this served to indicate a recent liver transplantation. 
 
The fourth time-dependent covariate, (iv) first alcohol-related hospital admission, served as a 
proxy for a history of problem alcohol use. For each DC patient, the occurrence of one or more 
alcohol-related episodes in their hospitalization history was coded using an indicator variable. 
This involved searching the linked hospitalization records for alcohol-related discharge diagnosis 
codes in either the main or a supplementary diagnosis field. The alcohol-related diagnosis codeset 
consisted of alcohol use (ICD-10 Z72.1), mental and behavioural disorders due to use of alcohol 
(ICD-10 F10; ICD-9: 291, 303, 305), degeneration of nervous system due to alcohol (ICD-10 G31.2, 
G62.1, G72.1, I42.6, K29.2; ICD-9 357.5, 425.5, 535.3), toxic effects of alcohol (ICD-10 T51.0, T51.9; 
ICD-9 980.0), alcoholic liver disease (ICD-10 K70.1-3, K70.9; ICD-9 571.0-571.3), alcohol-induced 
chronic pancreatitis (ICD-10 K86.0), evidence of alcohol involvement (ICD-10 Y90-1), finding of 
alcohol in blood (ICD-10 R78.0; ICD-9 790.3), alcohol rehabilitation (ICD-10 Z50.2), and accidental 
or intentional self-poisoning by and exposure to alcohol (ICD-10 X45, X65; ICD-9 E860.0, E860.9). 
 
Statistical analyses  
The average annual percentage change in the number of new DC patients, both overall and 
stratified by covariate level, was calculated by fitting Poisson regression models to the annual 
observed numbers over the period 1994–2013. Cumulative incidence plots, per outcome, were 
produced using a multistate modelling/competing risks approach (18). Transition probabilities 
between disease states were estimated using the same multistate model; we report annual values 
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by averaging over the estimated probabilities for each of the first three years of follow-up. 
 
Follow-up time  
We used standard person-time methodology. For each endpoint investigated, the follow-up period 
was defined to begin at the date of the first hospital admission with mention of DC, and to end at 
the earliest of the date the endpoint occurred or the right-censoring date (31 May 2014). Follow-up 
was also censored at date of death from a non-liver related cause or from any cause in the analyses 
of the endpoints liver-related mortality and first HCC admission, respectively. 
 
Cox regression analyses were carried out to estimate the relative risk (as hazard ratios) of all-cause 
and liver-related mortality associated with the covariates of interest (see above). Violation of the 
proportional hazards assumption was graphically assessed and additionally tested using 
Schoenfeld residuals.  
 
Finally, we assessed the presence and impact of potential referral bias that can be present when 
analysing a prevalent cohort (i.e., the chance of inclusion in the study population may be 
associated with the outcome(s) of interest; this may be the case for patients who died of DC that 
had been first diagnosed only at a very advanced stage). Therefore, as a sensitivity analysis the 
Cox regression analyses were repeated, but with the follow-up period re-defined to exclude the 
first 14 days after first DC admission. All statistical analyses were conducted using R software for 
statistical computing (19). 
 
RESULTS 
First-time hospitalization for DC  
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During the period 1994-2013, a total of 1,169 HCV chronically-infected persons were hospitalized 
with first-time mention of DC (Table 1). The majority were males (74%) and the most frequent age-
group was 40-49 years (39%). More than half (56%) had an alcohol-related admission prior to their 
first DC admission, and injecting drug use was indicated as the risk activity for acquiring HCV 
infection for 46% of the study population (85% of those with known risk). The number of new DC 
patients increased over time, from 63 (in the quinquennium 1994-1999) to 541 (in 2009-2013). Four 
percent were identified as HIV co-infected. The hierarchical classification of discharge diagnoses 
indicated that ascites was a more frequent complication (53%) than either hepatic failure or 
bleeding oesophageal varices. Fifty-four patients (5%) had a hospital admission with an HCC 
diagnosis code prior to their first DC admission (median of 124 days previously; IQR: 70-503 days). 
 
Annual change in the number of first-time admissions for DC 
The annual numbers of new DC patients, both overall and stratified by DC code category, is 
shown in Fig. 1a. The average annual percentage change in the numbers of DC patients by stratum 
of covariate is presented in Table 1. The average annual change in DC patient numbers increased 
over time, both overall (12.6% per year), and for all covariate strata. With respect to age, the largest 
average annual percentage change (15.9%) was observed for the 50-59 years age-group. 
 
Outcomes following first-time admission for DC 
Within the period 1 January 1994 through 31 May 2014, 722 and 95 DC patients died of a liver- or a 
non-liver related cause, respectively, and 106 DC patients had a subsequent first hospital 
admission for HCC. By the end of May 2014, 352 study cohort members were not known to have 
died. Median follow-up time for the mortality outcomes was 1.09 years (IQR: 0.22–3.47); for the 
outcome first subsequent HCC admission, median follow-up was 1.01 years (IQR: 0.18 –3.28), with 
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minimum and maximum follow-up times of 0 and 19.35 years. The cumulative annual number of 
patients with DC or with both DC and HCC and not known to have died, and the cumulative 
number of liver-related and non-liver related deaths, are shown in Fig. 1b. 
 
The rates of liver-related and non-liver related mortality dropped rapidly over the initial 6 months 
following first DC admission (very high in the first two-week period) and then decreased more 
gradually with time since DC (Supporting Information, Table S1). Mortality rates for both 
endpoints were relatively stable over the four quinquennia of the study period (data not shown). 
 
The annual transition probabilities between various disease states are shown in Fig. 2. The 
probability of a liver-related death following first DC admission was 20.9%, higher than the 
probability of either non-liver related death or first subsequent HCC admission (3.0% and 1.5% per 
year, respectively). Following the first subsequent HCC admission, the annual transition 
probabilities for liver-related and non-liver related mortality were 52.4% and 0%, respectively. Fig. 
3 shows the proportion of the DC cohort in each disease state (the state occupation probabilities) over 
the first nine years of follow-up. 
 
Survival analysis of time to outcome 
Fig. 4 shows the cumulative risks of each of the four outcomes; the cumulative risks for the same 
four endpoints but stratified according to DC code category and according to the occurrence of at 
least one alcohol-related admission prior to first DC admission are provided in Supporting 
Information, Figs. S1 and S2. The five-year cumulative risks of liver-related mortality, all-cause 
mortality, non-liver-related mortality and first subsequent HCC admission were 61.3%, 69.5%, 
8.2%, and 8.8%, respectively. If patients with an HCC admission prior to study entry are excluded, 
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the five-year cumulative risk of a first HCC admission decreases to 6.4%. 
 
The results of the multifactorial Cox proportional hazards regression analyses of liver-related and 
all-cause mortality are presented in Table 2, with univariate Cox regression results in Supporting 
Information, Table S2. The relative risk of liver-related death among DC patients was significantly 
increased for males (HR=1.3, 95% CI: 1.1-1.6), current age 60+ years (HR=1.5, 95% CI: 1.2-2.0) 
compared with 40-49 years, and HCC hospital admission (HR=2.7, 95% CI: 2.2-3.4). There was a 
reduced relative risk for non-PWID risk for HCV acquisition (HR=0.7, 95% CI: 0.5-1.0) compared 
with PWID, a primary discharge diagnosis of bleeding varices (HR=0.7, 95% CI: 0.6-1.0), compared 
with hepatic failure, the occurrence of a post-liver transplant admission (HR=0.2, 95% CI: 0.1-0.3), 
and period of first DC admission 1994-1998 (HR=0.6, 95% CI: 0.5-0.9), compared with 1999-2003. 
The relative risk of all-cause mortality followed a very similar pattern, with comparable HR 
estimates (Table 2). 
 
The frequency of the mortality outcomes investigated, when plotted as function of period of 
follow-up time (Supporting Information, Fig. S3) indicated a very high surge in events 
immediately following first DC admission. As a sensitivity analysis, we repeated the Cox 
regression analyses after excluding the first 14-days of follow-up. The resulting relative risk 
estimates were largely similar (see Supporting Information, Table S3). 
 
For liver-related deaths only, the five most frequently occurring ICD codes in the underlying cause 
of death field were K70.9, B182, C220, K703, and K704 (alcoholic liver disease, unspecified, chronic 
hepatitis C, liver cancer, cirrhosis, and alcoholic hepatic failure, respectively), which together accounted 
for 62% (445/ 722) of all liver-related deaths. For non-liver related deaths only, the five most 
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frequently occurring underlying cause of death ICD codes were R99, F112, F192, X42, and I189 
(other ill-defined and unspecified causes of mortality, mental/behavioural disorders due to use of 
opioids, mental/behavioural disorders due to multiple drug use, accidental poisoning by and 
exposure to narcotics and psychodysleptics, other noninfective disorders of lymphatic vessels and 
lymph nodes, respectively), which together accounted for 41% (39/95) of the total. 
 
DISCUSSION 
Scotland has been experiencing an epidemic of HCV-related decompensated cirrhosis. During the 
last 20 years, we observed a nine-fold increase in new HCV-related DC patients between 1994 and 
2013, with a corresponding rapid rise in the prevalent number of persons living with DC (Fig. 1). 
Besides the health burden of the disease itself, the financial burden to the Scottish health services 
for the management of chronic HCV-related severe disease will also have substantially increased. 
For example, based on estimated prices of managing DC and HCC (excluding liver transplantation 
costs)(20), the prevalent cohort of 379 chronic HCV patients with DC in 2013 (involving 109 
patients also with HCC) would have cost the NHS around £6.4 million in 2013. When compared 
with the health care costs associated with the prevalent cohort of 20 patients with DC in 1996 
(£305,000), this represents a 21-fold rise over a near 20-year period. 
 
Over the 20-year study period, we found no evidence for improvement in the relative risks of 
liver-related or all-cause mortality associated with quinquennium of first DC hospitalization. 
Despite remarkable increases in rates of referral to tertiary care (i.e., specialist liver clinics) and of 
initiation on antiviral treatment among HCV patients in recent years in Scotland (13), mortality 
outcomes failed to show parallel improvements once the DC stage of liver disease had been 
reached. Moreover, the five-year cumulative incidence of all-cause mortality was notably high – at 
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70% – in this DC patient population, even though we lacked accurate data on liver transplantation. 
In a comparable period (1996-2014, mostly overlapping our study period), there were 176 first liver 
transplants in HCV infected persons in Scotland (12); a proportion of the observed extended 
survival in DC pts with liver failure (see Fig. 3) may be due to successful transplantation (we 
estimate 50% as an upper bound; 176 represents 50% of our cohort´s 5-year survivors). However, 
in multifactorial analyses we did adjust for an indicator of past liver transplantation, which was 
associated with a considerable reduction in mortality risk.  
 
There have been few previous studies investigating the clinical course of disease in patients with 
HCV-related DC. In a cohort of 200 HCV-infected patients from two Barcelona liver clinics 
followed up for a mean of 2.8 years after their first hospital admission for DC, 17% developed 
HCC and all-cause mortality was 43% (21, 22). In a larger clinical cohort study involving 1,037 
HCV infected/HIV-uninfected persons from eight Spanish hospitals followed up for a median 13 
months, 37% of patients died, of which 86% was due to a liver-related cause (23). There is 
uncertainty, however, in generalising findings based on primarily academic research centre clinical 
populations, which may be subject to selection bias, to the wider DC patient population. For 
instance, five-year survival in DC patients reported for an HCV patient cohort (21) was notably 
better: 51% compared with 30% for our cohort; for comparison, the 5-year cumulative mortality 
incidence from a systematic review of disease progression in cirrhotic patients (not only due to 
HCV infection) is roughly 75% (24). Our estimate of the annual transition probability of death 
following DC (24%; summing liver-related and non-liver related causes) is also much higher than 
the pooled estimate of 14.5% arrived at via meta-analysis of three clinical cohorts (1, 2, 3, 25). 
 
Development of HCC or death following DC may be influenced by underlying co-morbidities (26). 
 McDonald   15 
For instance, our study population had a high baseline rate (56%) of prior hospitalization for an 
alcohol-related cause, which we included as an (imperfect) proxy for problem alcohol use. 
However, we found no evidence for an effect of alcohol-related hospitalization (proxy for problem 
alcohol use) on the relative risk of death, after adjusting for other covariates. Although Scotland’s 
HCV-diagnosed population has a high prevalence of problem alcohol use, alcohol-related liver 
disease as a co-morbid condition is also characteristic of other, mainly substance-abusing, HCV-
infected populations (26, 27) We emphasise the importance of quantifying the benefit of treatment 
with the new DAAs among all DC patients – including those with extensive co-morbidities – in 
terms of survival, and not just a sustained virological response (28). Record-linkage methods 
similar to those described here may prove useful for establishing the prognosis of patients treated 
with DAAs and attaining SVR post-DC diagnosis. 
 
Despite the power and large sample size afforded by our record-linkage study design (analysis of 
our nationwide cohort – comprised of patients from approximately 200 hospitals – largely 
overcomes the above-mentioned limitation inherent with study populations of patients attending 
tertiary care clinics), we note the existence of several limitations. First, we lacked data informing 
liver disease prognosis, such as provided by a Child-Pugh or MELD score. 
 
Second, our information on HIV co-infection, which has been associated with an increased relative 
risk of mortality in DC patients (reported hazard ratio of 2.3 (23)), may have been impoverished as 
it was derived from hospitalization history. However, the percentage of HIV co-infected DC 
patients (4.4%) is comparable to that reported in the previous Scottish study (9) that employed 
record-linkage to the national HIV register, which found 2.3% of the HCV-diagnosed study 
population to be HIV co-infected. 
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Third, we defined the covariate alcohol-related hospitalization to serve as a proxy for problem 
alcohol use, as no quantitative data on alcohol consumption by our study population were 
available. This measure is only a crude indicator of problem alcohol use (although alcohol-related 
admission rates have been shown to correlate with self-reported intake; (29)). This suggests a 
reason for the observed lack of association of this covariate with mortality in multifactorial 
analysis. 
 
Our study inclusion criteria required a first hospital admission for DC. Record-linkage to hospital 
inpatient data should have high sensitivity as almost all DC patients will be admitted to hospital. 
However, an unknown number of persons developing DC and who were not admitted to hospital 
will have been excluded. This number is likely to be very small given that in the previous Scottish 
record-linkage analysis of HCV-diagnosed patients developing DC in the period 1996-2006 (9), 
only 6% (63/1058) of those patients who had died with mention of DC in their death record had not 
been previously admitted to hospital. Finally, we have not been able to follow-up those DC 
patients who were hospitalized or who had died outwith Scotland, although these numbers are 
anticipated to be small. 
 
Conclusions 
Over the last 20 years, there has been no observable improvement in severe outcomes among HCV 
chronically-infected patients in Scotland who have developed decompensated cirrhosis. The 
annual numbers of incident and prevalent DC cases showed a rising trend, and the relative risks of 
all-cause and liver-related death did not vary over the study period. The present results are 
important for establishing the expected risks of severe disease outcomes among DC patients in the 
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interferon-based treatment era, and will be useful for calibrating and/or validating HCV disease 
projection and health economic models (30-32). Further monitoring of the numbers of incident and 
prevalent DC cases, and the risks of death and complications among persons with DC, is of utmost 
importance in the era of new DAA treatments. 
 
ACKNOWLEDGEMENTS 
We thank the Hepatitis C Clinical Database Monitoring committee, clinical data entry staff and the 
following virologists for their support with the HCV Diagnosis database: Dr Sheila Burns (East of 
Scotland Specialist Virology Centre, Royal Infirmary of Edinburgh, Edinburgh), Dr Sheila 
Cameron (West of Scotland Specialist Virology Centre, Gartnavel General Hospital, Glasgow), Dr 
Paul McIntyre (Department of Medical Microbiology, Ninewells Hospital and Medical School, 
Dundee) and Dr Pamela Molyneaux (Department of Medical Microbiology, University Medical 
School, Foresterhill, Aberdeen). 
 
STATEMENT OF INTERESTS 
HAI reports personal fees from Janssen and speaker fees from Gilead, outside the submitted work. 
SJH has received honoraria for presenting at meetings/conferences from Abbvie, Gilead, Janssen, 
MSD, Roche.  
  
 McDonald   18 
REFERENCES 
1. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: 
A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112(2): 463-472. 
2. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural 
history of compensated cirrhosis: A cohort study of 297 patients. Am J Gastroenterol 2002; 97(11): 
2886-2895. 
3. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-
related cirrhosis and history of parenteral exposure in the united states. Hepatology 1999; 29(4): 
1311-1316. 
4. Iacobellis A, Perri F, Valvano MR, et al. Long-term outcome after antiviral therapy of patients 
with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol 2011; 
9(3): 249-253. 
5. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with 
hepatitis C virus and decompensated cirrhosis: A controlled study. J Hepatol 2007; 46(2): 206-212. 
6. Bailly F, Pradat P, Virlogeux V, et al. Antiviral therapy in patients with hepatitis C virus-induced 
cirrhosis. Dig Dis 2015; 33(4): 613-623. 
7. Gambato M, Lens S, Navasa M, et al. Treatment options in patients with decompensated 
cirrhosis, pre- and post-transplantation. J Hepatol 2014; 61(1 Suppl): S120-31. 
8. Honer Zu Siederdissen C, Maasoumy B, Deterding K, et al. Eligibility and safety of the first 
interferon-free therapy against hepatitis C in a real-world setting. Liver Int 2015; 35(7): 1845-1852. 
9. McDonald SA, Hutchinson SJ, Bird SM, et al. Hospitalization of hepatitis C-diagnosed 
individuals in scotland for decompensated cirrhosis: A population-based record-linkage study. 
 McDonald   19 
Eur J Gastroenterol Hepatol 2010; 22(1): 49-57. 
10. Shaw L, Taylor A, Roy K, et al. Establishment of a database of diagnosed HCV-infected persons 
in Scotland. Commun Dis Public Health 2003; 6(4): 305-310. 
11. Health Protection Scotland (HPS). Surveillance of known hepatitis C antibody positive cases in 
Scotland: Results to 31 December 2013. HPS Weekly Report: Health Protection Scotland 2014; 
18(2011/18): 243-249. 
12. Costella A, Goldberg D, Harris H, et al. Hepatitis C in the UK 2015 Report. London: Public 
Health England, 2015. 
13. McDonald SA, Innes HA, Hayes PC, et al. What is the impact of a country-wide scale-up in 
antiviral therapy on the characteristics and sustained viral response rates of patients treated for 
hepatitis C? J Hepatol 2015; 62(2): 262-268. 
14. Kendrick S, Clarke J. The Scottish Record Linkage System. Health Bulletin (Edinburgh) 1993; 
51(72-79). 
15. Innes HA, McDonald SA, Dillon JF, et al. Toward a more complete understanding of the 
association between a hepatitis C sustained viral response and cause-specific outcomes. 
Hepatology 2015; 62(2): 355-364. 
16. Ioannou GN, Bryson CL, Weiss NS, et al. The prevalence of cirrhosis and hepatocellular 
carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57(1): 249-
257. 
17. Aspinall EJ, Hutchinson SJ, Janjua NZ, et al. Trends in mortality after diagnosis of hepatitis C 
virus infection: An international comparison and implications for monitoring the population 
impact of treatment. J Hepatol 2015; 62(2): 269-277. 
 McDonald   20 
18. Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: The importance of 
multistate models and competing risks analysis. Hepatology 2015; 62(1): 292-302. 
19. R Development Core Team. R: A language and environment for statistical computing. Vienna, 
Austria: R Foundation for Statistical Computing, 2014. 
20. Martin NK, Hickman M, Miners A, et al. Cost-effectiveness of HCV case-finding for people 
who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ 
Open 2013; 3(8): 10.1136/bmjopen-2013-003153. 
21. Planas R, Balleste B, Alvarez M, et al. Natural history of decompensated hepatitis C virus-
related cirrhosis: A study of 200 patients. J Hepatol 2004; 40(5): 823-830. 
22. Sola R, Alvarez M, Balleste B. Probability of liver cancer and survival in HCV-related or 
alcoholic-decompensated cirrhosis. A study of 377 patients Liver Int; 2006(26): 1. 
23. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of 
patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41(4): 779-789. 
24. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in 
cirrhosis: A systematic review of 118 studies. J Hepatol 2006; 44(1): 217-231. 
25. Hutchinson S, Bird S, Goldberg D. Modeling the current and future disease burden of hepatitis 
C among injection drug users in Scotland. Hepatology 2005; 42(3): 711-23. 
26. Innes H, Hutchinson SJ, Obel N, et al. Liver mortality attributable to chronic hepatitis C virus 
infection in Denmark and Scotland: Using spontaneous resolvers as the benchmark comparator. 
Hepatology 2016; . 
27. Prasad L, Spicher VM, Negro F, et al. Little evidence that hepatitis C virus leads to a higher risk 
of mortality in the absence of cirrhosis and excess alcohol intake: The Swiss hepatitis C cohort 
 McDonald   21 
study. J Viral Hepat 2009; 16(9): 644-649. 
28. Husing A, Kabar I, Schmidt HH, et al. Hepatitis C in special patient cohorts: New opportunities 
in decompensated liver cirrhosis, end-stage renal disease and transplant medicine. Int J Mol Sci 
2015; 16(8): 18033-18053. 
29. McDonald SA, Hutchinson S, Bird S, et al. Association of self-reported alcohol use and 
hospitalization for an alcohol-related cause in scotland: A record-linkage study of 23,183 
individuals. Addiction 2009; 104(4): 593-602. 
30. Martin NK, Vickerman P, Miners A, et al. The cost-effectiveness of HCV antiviral treatment for 
injecting drug user populations. Hepatology 2012; 55: 49-57. 
31. Younossi ZM, Singer ME, Mir HM, et al. Impact of interferon free regimens on clinical and cost 
outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60(3): 530-537. 
32. McEwan P, Ward T, Bennett H, et al. Estimating the clinical and economic benefit associated 
with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 
2015; 10(1): e0117334. 
 
SUPPLEMENTARY MATERIAL 
Document file: Supporting_Information_McDonald_JVH.pdf   
 McDonald   22 
Table 1. Baseline characteristics of HCV chronically-infected patients with decompensated 
cirrhosis (DC). 
 
Factor Level N (%) Annual % change** 
Sex Males 862 (73.7) 12.3 
 Females 306 (26.2)  13.5 
 NK 1 (0.1)  – 
 
Age at first DC <40 304 (26.0)  10.2 
 hospital admission 40-49 451 (38.6)  13.4 
 (years) 50-59 278 (23.8)  15.9 
    60+ 136 (11.6)  10.1 
 
Year of first DC 1994-1998 63 (5.4)  – 
 admission 1999-2003 200 (17.1)  – 
 2004-2008 365 (31.2)  – 
    2009-2013 541 (46.3)  – 
 
≥1 Alcohol-related Yes 650 (55.6)  13.8 
 admission prior to No 519 (44.4)  11.3 
 first DC admission  
 
Risk group PWID (ever) 532 (45.5)  14.5 
 Non-PWID 96 (8.2)  12.0 
 Not known 541 (46.3)  7.1 
 
DC diagnosis Hepatic failure 419 (35.8)  12.0 
  code category* Ascites 614 (52.5)  14.1 
   Bleeding varices 135 (11.6)  8.6 
 
HIV code in  Yes 51 (4.4)  6.2 
  any admission No 1118 (95.6)  13.0 
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≥1 admission for Yes 54 (4.6)  20.9 
 HCC prior to first No 1115 (95.4)  12.3 
 DC admission  
 
Time since HCV -1 to 0 years since HCV 146 (12.5)  6.2 
  diagnosis date 0 to <1 year since HCV 207 (17.7)  7.5 
  (years) 1 to <3 years 194 (16.6)  8.9 
 3 to <5 years 149 (12.7)  10.2 
 5 to <10 years 268 (22.9)  16.1 
 10+ years 205 (17.5)  32.6 
  
Note: Study population is defined as first hospital admission with mention of DC occurring within 
the period 1994-2013 (n = 1,169). The average annual percent change over the study period in the 
number of DC patients is also shown (12.6% overall). 
PWID = people who inject drugs; HCC = hepatocellular carcinoma.  
* Because more than one code category can appear in the hospital episode record of an individual 
patient, a hierarchical definition was used; e.g., if a hepatic failure code occurs in one of six 
possible diagnosis fields: DIAG1 (primary diagnosis) through DIAG6 (supplementary diagnoses), 
the patient will be counted as such, even if one or more of the other code categories also occurred 
in the hospital record. If no hepatic failure code but an ascites code occurs in any of the diagnosis 
fields, then category ‘ascites’ is assigned, and so forth.  
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Table 2. Results of multifactorial Cox proportional hazards regression analysis of patient and other 
characteristics on various endpoints (1994 to 31 May 2014) in HCV chronically-infected DC 
patients.   
Risk Liver-related death (n=722) All-cause death (n=817)  
Factor n    pyrs     HR 95% CI n    pyrs        HR 95% CI  
Sex  F   167 857   Ref. 191 857  Ref.  
       M 555 2133 1.30 1.09-1.55 626 2133 1.28 1.09-1.52  
 
Current age (years) 
  <40 132 621 0.97 0.78-1.20 152 621 0.94 0.77-1.14   
  40-49 266 1155  Ref. 311 1155  Ref.   
  50-59 200 811 1.02 0.84-1.23 219 811 0.99 0.83-1.19  
  60+ 124 402 1.53 1.20-1.95 135 402 1.52 1.21-1.91  
 
Alcohol-related hospitalization 
 No 185 798    Ref. 207 798  Ref.   
 Yes 537 2191 1.07 0.89-1.28 610 2191 1.05 0.88-1.25  
 
Period of first DC hospital admission 
  1994-98   42 384 0.64 0.46-0.91 52 384 0.70 0.51-0.96  
  1999-03   145 802  Ref. 167 802  Ref.   
  2004-08 262 1031 1.08 0.88-1.33 292 1031 1.06 0.87-1.29  
  2009-13 273 773 1.06 0.86-1.31 306 773 1.06 0.87-1.29  
 
Risk group for acquisition of HCV infection 
  PWID 307  1326  Ref. 365 1326  Ref.   
  NonPWID 54 360 0.72 0.53-0.98 62 360 0.70 0.53-0.93  
  NK 361 1304 1.15 0.97-1.37 390 1304 1.07 0.91-1.26  
 
DC code category 
  Hepat. failure 265 1044  Ref. 298 1044  Ref.  . 
  Ascites 377 1512 0.91 0.77-1.06 428 1512 0.93 0.80-1.08  
  Varices 80 434 0.74 0.58-0.96 91 434 0.76 0.60-0.97  
 
HCC admission prior to first DC admission 
  No 618 2822  Ref. 713 2822  Ref.  
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  Yes 104 168 2.71  2.15-3.42 104 168 2.50 1.99-3.14  
 
HIV co-infection 
  No 689 2886  Ref. 775 2886  Ref. . . 
  Yes 33 104 1.42 0.99-2.04 42 104 1.57 1.13-2.16  
 
Post-liver transplantation admission 
  No 698 2653  Ref. 793 2653  Ref. . . 
  Yes 24 337 0.22 0.14-0.34 24 337 0.20 0.13-0.31  
 
Note. Study population defined as patients with first DC hospital admission in period 1994–2013; n=1,169. 
Current age, alcohol-related hospitalization, admission for HCC, and post-liver transplantation admission 
are coded as time-dependent covariates. Boldface indicates conventional statistical significance. 
NK = not known; PWID = people who inject drugs; HCC = hepatocellular carcinoma. 
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FIGURE LEGENDS 
Fig. 1. Annual numbers of first DC hospital admissions (panel A) and cumulative annual numbers 
of deceased and living DC patients (B), over the period 1994–2013. 
Fig. 2. Annual transition probabilities of various outcomes following first hospital admission with 
DC among persons chronically-infected with HCV in Scotland (study period 1 January 1994 to 31 
May 2014). Values are averages of the individual transition probabilities for the first three years of 
follow-up. Annual mortality probabilities within square brackets are calculated with the first 14 
days of follow-up excluded.  
Fig. 3. Proportion of DC patient cohort as a function of time since first DC admission occupying 
the following disease states: decompensated cirrhosis (alive), HCC (alive), dead following HCC, 
and dead without HCC. The area shaded black represents the proportion of the DC patient cohort 
living with HCC. 
Fig. 4. Cumulative risk of four specified endpoints among DC patients (defined as HCV 
chronically-infected persons who had their first DC hospital admission in the period 1994–2013) 
following first DC admission: for liver-related death (A), all-cause death (B), first HCC hospital 
admission (C), and non-liver related death (D).  Follow-up time in each plot is censored on the last 
day of study period (31 May 2014). 
 
 
 
 
